720MO IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced gynecological cancers (Gynecol C): Results from a phase I study

Jian Shu(Fuzhou University), Qi Zhou(Fudan University), Rui An(The Eighth Hospital of Xi'an), Huaqiang Zhou(Sun Yat-sen University), L. Zhu(Nanjing Drum Tower Hospital), Xi Chen(Jilin Province Science and Technology Department), Zhiyong Zhang(Institute of Geology and Geophysics), Guoqiang Li(Southwest University of Science and Technology), Xiaolin Wang(University of Toronto), Qian Zhu(Panzhihua Central Hospital), Huiping Liu(Guangxi University), Xiaohong Xu(Zhejiang Cancer Hospital), Yunchao Huang(North China University of Water Resources and Electric Power), Jie Tang(Central South University), Ting Zhu(The First People's Hospital of Jiangxia District), Wen Cheng(Tongji University), Qinghua Xu(Anhui Academy of Medical Sciences), Hui Zhao, Jie Gao(Jiangxi Provincial Cancer Hospital), Ruixia Guo(Shanghai Ninth People's Hospital)
Annals of Oncology
September 1, 2024
Cited by 6


Related Papers